BR112020018981A8 - Combinação de anticorpo anti-hgfr e hegfr para o tratamento de um tumor e/ou metástase - Google Patents

Combinação de anticorpo anti-hgfr e hegfr para o tratamento de um tumor e/ou metástase

Info

Publication number
BR112020018981A8
BR112020018981A8 BR112020018981A BR112020018981A BR112020018981A8 BR 112020018981 A8 BR112020018981 A8 BR 112020018981A8 BR 112020018981 A BR112020018981 A BR 112020018981A BR 112020018981 A BR112020018981 A BR 112020018981A BR 112020018981 A8 BR112020018981 A8 BR 112020018981A8
Authority
BR
Brazil
Prior art keywords
hgfr
antibody fragment
metastasis
tumor
treatment
Prior art date
Application number
BR112020018981A
Other languages
English (en)
Other versions
BR112020018981A2 (pt
Inventor
Basilico Cristina
Vigna Elisa
Maria Comoglio Paolo
Original Assignee
Metis Prec Medicine Sb S R L
Vertical Bio Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metis Prec Medicine Sb S R L, Vertical Bio Ag filed Critical Metis Prec Medicine Sb S R L
Publication of BR112020018981A2 publication Critical patent/BR112020018981A2/pt
Publication of BR112020018981A8 publication Critical patent/BR112020018981A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fragmento de anticorpo anti-HGFR em combinação com uma porção extracelular do HGFR humano para o uso no tratamento de um paciente sofrendo de um tumor e/ou metástase, em que: (i) o fragmento de anticorpo anti-HGFR tem apenas um parátopo capaz de se ligar a um epítopo da porção extracelular de HGFR humano e tem atividade antagonística para HGFR, (ii) a porção extracelular de HGFR humano é capaz de ligação ao HGF em uma maneira estável e contém pelo menos uma mutação de aminoácido no epítopo reconhecido pelo fragmento de anticorpo anti-HGFR para impedir a ligação do fragmento de anticorpo anti-HGFR ao mesmo, e (iii) o fragmento de anticorpo anti-HGFR e a porção extracelular de HGFR humano são adequados para a administração ao paciente (a) em uma forma de proteína ou (b) em uma forma de ácido nucléico.
BR112020018981A 2018-03-22 2019-03-21 Combinação de anticorpo anti-hgfr e hegfr para o tratamento de um tumor e/ou metástase BR112020018981A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102018000003875 2018-03-22
IT102018000003875A IT201800003875A1 (it) 2018-03-22 2018-03-22 Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
IB2019180658 2019-09-26

Publications (2)

Publication Number Publication Date
BR112020018981A2 BR112020018981A2 (pt) 2021-01-05
BR112020018981A8 true BR112020018981A8 (pt) 2022-06-28

Family

ID=62530500

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020018981A BR112020018981A8 (pt) 2018-03-22 2019-03-21 Combinação de anticorpo anti-hgfr e hegfr para o tratamento de um tumor e/ou metástase

Country Status (13)

Country Link
US (1) US11814433B2 (pt)
EP (1) EP3768710A1 (pt)
JP (1) JP7381555B2 (pt)
KR (1) KR20200135449A (pt)
CN (1) CN112041340A (pt)
AU (1) AU2019240274A1 (pt)
BR (1) BR112020018981A8 (pt)
CA (1) CA3093513A1 (pt)
IL (1) IL277476A (pt)
IT (1) IT201800003875A1 (pt)
MX (1) MX2020009787A (pt)
SG (1) SG11202008612XA (pt)
WO (1) WO2019180658A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017135251A1 (ja) * 2016-02-02 2017-08-10 国立研究開発法人物質・材料研究機構 強磁性トンネル接合体、これを用いた磁気抵抗効果素子及びスピントロニクスデバイス並びに強磁性トンネル接合体の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1959955T1 (sl) 2005-12-05 2011-02-28 Pfizer Prod Inc Postopek zdravljenja abnormalne celične rasti
AU2007213804B2 (en) * 2006-02-06 2012-12-13 Vertical Bio Ag Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
CN101914161B (zh) * 2010-08-13 2013-12-11 四川大学 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
ITTO20130012A1 (it) * 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi

Also Published As

Publication number Publication date
CA3093513A1 (en) 2019-09-26
JP2021518170A (ja) 2021-08-02
CN112041340A (zh) 2020-12-04
KR20200135449A (ko) 2020-12-02
US20210070868A1 (en) 2021-03-11
IL277476A (en) 2020-11-30
US11814433B2 (en) 2023-11-14
EP3768710A1 (en) 2021-01-27
JP7381555B2 (ja) 2023-11-15
RU2020129465A (ru) 2022-04-22
WO2019180658A1 (en) 2019-09-26
AU2019240274A1 (en) 2020-10-15
IT201800003875A1 (it) 2019-09-22
SG11202008612XA (en) 2020-10-29
MX2020009787A (es) 2020-11-09
BR112020018981A2 (pt) 2021-01-05

Similar Documents

Publication Publication Date Title
BR112019005823A2 (pt) tratamento para enxaqueca refratária
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112017012600A2 (pt) complexo de proteína de interleucina 15 e uso do mesmo
BR112022004474A2 (pt) Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta
BR112017016336A2 (pt) proteínas de ligação icos agonistas?
EA201890278A1 (ru) Антитела к pd-l1
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BR112016011025A2 (pt) polipeptídeos anticorpo e seus usos
BR112015032690A8 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
DE602004028651D1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
BR112013009157A2 (pt) polipeptídeos com atividade de permease
EA201891913A1 (ru) Улучшенные препараты клеток-предшественников взрослой печени
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
BR112019008279A2 (pt) uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MX2021006980A (es) Anticuerpos anti-il-27 y usos de estos.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
BR112017003487A2 (pt) ?anticorpo totalmente humano, fragmento de fab de anticorpo totalmente humano, anticorpo humano de fita simples, anticorpo de fita simples totalmente humano, método de tratamento de amplo espectro de cânceres e método de tratamento de distúrbios inflamatórios?

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: VERTICAL BIO AG (CH)